Hong Kong equities extended their losing streak as escalating Middle East tensions and rising oil prices stoked inflation concerns. A combination of factors, including clinical trial risk events, pulled down the innovative drug sector, while the banking segment saw a modest broad uptick, buoyed by private placement policy benefits and robust interim earnings. At the close, the Hang Seng Index fell 1.27% to 24,954.47 points, with total turnover reaching HK$198.865 billion; the Hang Seng Tech Index dropped 2.04% to 4,330.49 points.
Among the top Hong Kong-listed ETFs by size, Tracker Fund (02800) slipped 1.01% to HK$25.58, CSOP Hang Seng Tech Index ETF (03033) declined 1.89% to HK$4.25, and CSOP SK Hynix Daily Leveraged (2x) Product (07709) fell 1.03% to HK$44.10.
Weighing on the innovative drug sector were three key headwinds: volatile overseas interest rate expectations, rising oil-driven inflation worries, and a single clinical setback. On September 9, the U.S. Treasury set the next day's long-term bond buyback face value cap at $6 billion—triple the previous level but still below the market's $10 billion forecast—pushing the 10-year Treasury yield to 4.85% intraday, which pressured high-valuation assets. Meanwhile, an overseas pharma company announced on September 8 that its Phase III trial missed its primary endpoint, triggering a 13% share price plunge and dampening near-term risk appetite. Additionally, the 2026 National Reimbursement Drug List negotiation and commercial insurance innovative drug pricing talks concluded on September 9, entering a waiting period with the new list expected in November, prompting early policy-driven capital to lock in gains.
Bank stocks posted steady gains, supported by both policy tailwinds and earnings resilience. On September 6, two major state-owned banks unveiled private placement plans to raise a combined no more than 260 billion yuan, entirely earmarked to replenish core Tier 1 capital. Of this, 200 billion yuan will come from newly issued special treasury bonds under the 2026 fiscal framework. According to China Post Securities, this capital injection significantly bolsters financial institutions' risk resilience, with a relatively limited dilution impact on earnings per share. In the first half of the year, A-share listed banks collectively generated approximately 3.14 trillion yuan in operating revenue, up 7.42% year-on-year, while net profit attributable to shareholders reached about 1.13 trillion yuan, up roughly 3%. For the first time in a decade, the six largest state-owned banks simultaneously raised their dividend payout ratios. Zhongtai Securities noted that banks' medium-to-long-term return on equity remains relatively stable, offering dependable dividends and attractive yields, making ROE and dividend income a high-certainty investment proposition.
From an institutional perspective, Zhongtai International observed that Hong Kong's major indices fell for a third straight session, reflecting cautious market sentiment. Huatai Securities suggested that the market currently lacks a clear new direction, with moves dominated by macro uncertainties. Until decisive economic data emerges, sustained trends in either direction are unlikely, and investors are advised to maintain balanced positioning, prioritize dividend-yielding core holdings, and manage exposure to U.S. Treasury yield beta.
In ETF developments, the N.A. Stock ETF Southern (515440.SH) debuted on its first trading day, closing 1% lower at 0.991 yuan with turnover of 54.6437 million yuan. The fund tracks the CSI A-Share Index, a broad-based benchmark covering all A-share listed companies on the Shanghai and Shenzhen exchanges, designed to reflect the overall performance of the A-share market. Consequently, the fund's industry coverage is exceptionally wide, spanning finance, information technology, industrials, consumer, healthcare, energy, materials, and other major economic sectors.